BRAF and non-small cell lung carcinoma: While early studies demonstrated some effectiveness of single-agent BRAF inhibitors in the treatment of NSCLC patients with V600E (p.Val600Glu, c.1799T>A) BRAF gene mutation, combining BRAF and MEK (Mitogen-Activated Protein Kinase Kinase 1) inhibitors (dabrafenib with trametinib) has shown even greater efficiency [13,14,15].